FDA approves BMS schizophrenia drug, bluebird bio announces layoffs, J&J talc subsidiary files for bankruptcy [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good —FDA approves BMS schizophrenia drug 

The bad — bluebird bio announces layoffs 

The ugly —J&J talc subsidiary files for bankruptcy